Evidence map›Paper›PMID 41492975›Full record

SynthesisJournal of comparative effectiveness research2026

Population-adjusted network meta-analyses provide new insights into the efficacy of treatment alternatives for metastatic castration-sensitive prostate cancer.

Neal Shore, Alicia K Morgans, Noman Paracha, Howard Thom, Edna Keeney, Philip Orishaba, David Phillippo, David Aceituno, Christopher Jd Wallis, Elaine Gallagher and 1 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of comparative effectiveness research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Neal ShoreCarolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA.ORCID 0000-0001-5767-0548
Alicia K MorgansDana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-6563-4587
Noman ParachaBayer Pharmaceuticals, Basel, Switzerland.ORCID 0000-0002-3438-4853
Howard ThomClifton Insight, Bristol, UK.ORCID 0000-0001-8576-5552
Edna KeeneyClifton Insight, Bristol, UK.ORCID 0000-0002-4763-8891
Philip OrishabaClifton Insight, Bristol, UK.ORCID 0000-0002-1236-8529
David PhillippoUniversity of Bristol, Bristol, UK.ORCID 0000-0003-2672-7841
David AceitunoClifton Insight, Bristol, UK.ORCID 0000-0002-2967-5816
Christopher Jd WallisDivision of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-5990-4026
Elaine GallagherBayer Pharmaceuticals, Basel, Switzerland.ORCID 0000-0001-6013-3276
Martin BoegemannUniversity of Muenster Medical Center, Department of Urology, Muenster, Germany.ORCID 0000-0002-2569-4446

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Androgen AntagonistsAntineoplastic Combined Chemotherapy ProtocolsProstatic Neoplasms, Castration-ResistantDocetaxelHumansMaleNetwork Meta-Analysis as TopicPyrazolesTreatment OutcomeAndrogen AntagonistsdarolutamideDocetaxelPyrazolescastration-sensitive prostate cancermulti-level network meta-regressionnetwork meta-analysisnetwork meta-interpolation

Identifiers

PMID41492975
PMCPMC12884344

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.